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Abstract
Angiogenesis is a critical component of the proliferative endometrial phase of the menstrual cycle.
Thus, we hypothesized that a stem cell-like population exist and can be isolated from menstrual
blood. Mononuclear cells collected from the menstrual blood contained a subpopulation of
adherent cells which could be maintained in tissue culture for >68 doublings and retained
expression of the markers CD9, CD29, CD41a, CD44, CD59, CD73, CD90 and CD105, without
karyotypic abnormalities. Proliferative rate of the cells was significantly higher than control
umbilical cord derived mesenchymal stem cells, with doubling occurring every 19.4 hours. These
cells, which we termed "Endometrial Regenerative Cells" (ERC) were capable of differentiating into
9 lineages: cardiomyocytic, respiratory epithelial, neurocytic, myocytic, endothelial, pancreatic,
hepatic, adipocytic, and osteogenic. Additionally, ERC produced MMP3, MMP10, GM-CSF,
angiopoietin-2 and PDGF-BB at 10–100,000 fold higher levels than two control cord blood derived
mesenchymal stem cell lines. Given the ease of extraction and pluripotency of this cell population,
we propose ERC as a novel alternative to current stem cells sources.
Introduction
Stem cells are undifferentiated cells that can replicate
themselves without differentiating, and under specific
conditions can differentiate into various specialized cell
types. Stem cell therapy holds tremendous promise for
repair and/or regeneration of aging and damaged tissue.
Broadly speaking, stem cells can be divided into embry-
onic and adult types. While embryonic stem cells possess
great ability to proliferate, the specific induction of their
controlled differentiation has been elusive [1-3]. Addi-
tionally, embryonic stem cells possess the possibility of
immune rejection of their differentiated progeny [4]. The
fear of embryonic stem cells causing teratomas has also
been a major obstacle to their clinical development [5].
Adult stem cells derived from tissues such as bone marrow
[6], cord blood [7], adipose tissue [8] or the amniotic
fluid [9] have demonstrated regenerative potential in a
variety of diseases and degenerative disorders, however,
these cells types are limited by: availability, invasiveness
of extraction, and in some cases limited proliferative
capacity. What is currently needed is a source of stem cells
that overcomes these deficiencies, while not possessing
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the fear of karyotypic abnormalities during culture and
possibility of oncogenesis.
The monthly preparation of the endometrium for receiv-
ing of the fertilized egg is associated with a period of
hyperproliferation and angiogenesis [10]. The lining of
the endometrium expands by 5–7 mm in thickness within
each menstrual cycle [11]. Given this very rapid angiogen-
esis, a great amount of tissue remodeling, growth factor
secretion, and endothelial sprouting must occur in a
tightly regulated manner. It is known that in certain con-
ditions of hyperangiogenesis, such as in cancer, stem cells
with angioblast properties migrate from the bone marrow
and actively participate in the angiogenic cascade [12].
Accordingly, we sought to investigate whether cells with
stem cell like properties may be found in the menstrual
blood during periods of menstruation.
We identified an adherent cell population possessing
non-hematopoietic markers that effectively could be
propagated for > 68 doublings while maintaining karyo-
typic normality and ability to differentiate into numerous
tissues. These cells, which we have termed Endometrial
Regenerative Cells (ERC), may be easily expandable and
useful for females as a non-invasively obtained and ethi-
cally appropriate autologous stem cell alternative.
Materials and methods
Generation of endometrial regenerative cells
Menstrual blood was collected from a healthy female sub-
ject after menstrual blood flow initiated. Collection was
performed in a urine cup and then transferred into a 5 ml
tube with 0.2 ml amphotericin B (Sigma-Aldrich, St Louis,
MO), 0.2 ml penicillin/streptomycin (Sigma 50 ug/nl)
and 0.1 ml EDTA-Na2 (Sigma) in phosphate buffered
saline (PBS). Mononuclear cells derived from menstrual
blood were separated by Ficoll-Paque (Fisher Scientific,
Portsmouth NH) according to the instruction and washed
in PBS. Cells were subsequently cultured in a Petri dish
(Corning, Acton, MA) containing DMEM medium sup-
plemented with 1% penicillin/streptomycin, 1% ampho-
tericin B, 1% glutamine and 20% FBS (completed
DMEM). Media was changed the next day. Adherent cells
were detached by trypsin and cultured in a T75 flask
(Fisher Scientific, Portsmouth NH) at 1 × 105 cells. The
cells were then subcultured and passaged twice a week.
Cloning of cells was accomplished by plating cells at a
concentration of approximately 1 cell per well in 96 well
plates (Corning, Acton, MA).
Phenotypic characterization
For fluorescent antibody cell surface staining cells were
washed with HBSS+2%BSA two times and incubated with
the specific antibody at concentrations recommended by
the respective manufacturer. Cells were incubated for 20
min and analyzed either under fluorescent microscope or
flow cytometry. The antibodies used were: CD markers,
SSEA-4, Stro-1, HLA-ABC and HLA-DR. These were pur-
chased from BD Pharmingen, Ancell, Stem Cell Technol-
ogies, eBioscience, Chemicom, Miltenyi Biotech and R&D
Systems. For intracellular staining by the antibodies with-
out any conjugate, cells were washed twice in Hank's solu-
tion with 2% BSA and fixed with 4% Formalin for 1 hour.
Subsequently cells were washed twice in 0.5% Tween20
and 0.1% Triton X-100 in PBS (T-PBS). Primary antibod-
ies were added to T-PBS at the concentrations recom-
mended by the manufacturer. Incubation was performed
for 30 min. Cells were then washed twice in T-PBS. Corre-
sponding secondary antibodies with fluorescent conju-
gates were subsequently diluted in T-PBS at the
concentrations suggested by the manufacture instruc-
tions. Incubate was performed for 20 min and cells were
analyzed using fluorescent microscopy or flow cytometry.
The intracellular antibodies used were Oct-4, Nanog and
telomerase (clone Y182, hTert: Abcam).
Karyotypic analysis
FPB cells were sent to NeoDiagnostix, Inc. (Rockville MD)
for karyotypic analysis. Cells were harvested at 70–80%
confluency and resuspended in 10 microliters of colcemid
per ml of media. Cells were incubated at 37°C for 3–6 hrs
after which cells were resuspended in 0.5 ml medium and
mixed with 0.075 M KCl to a volume of 10 ml. After incu-
bation for 10–15 min at 37°C in a waterbath cells were
resuspended to in a total of 10 ml fixative (methonal:ace-
tic acid as 3:1). Staining with DAPI for G-banding was per-
formed by equilibrating the slides in 0.3 M sodium citrate,
containing 3 M NaCl for 5 min and subsequent addition
of 2 drops of Antifade with DAPI per slide prior to visual-
ization.
Proteomic analysis
Conditioned media from different cell lines was sent to
RayBiotech, Inc (Norcross GA) for cytokine array analysis.
According to the company's sample preparation instruc-
tions, the media were changed to DMEM with 0.2% fetal
calf serum. Each flask was rinsed with 10 ml of this media
and refilled to 7 ml. After culture for two days, the media
was removed and centrifugation at 2000 rpm for 10 min-
utes was performed to remove cellular debris and frozen
at -70°C for shipping. The cell number in culture was used
to calculate the cytokine yield (pg) per million cells.
DMEM with 0.2% fetal calf serum (control media) with
no cells was sent for the analysis as well.
Differentiation
Adipogenic differentiation
ERC were seeded at a concentration of 4 × 10[4] cells/ml
in an 8 well chamber slide (Lab-Tek, Campbell, CA) with
0.5 ml media per well. When the cells reached 100% con-Journal of Translational Medicine 2007, 5:57 http://www.translational-medicine.com/content/5/1/57
Page 3 of 10
(page number not for citation purposes)
fluence they were transferred to Adipogenic Induction
Media (Cambrex, East Rutherford, NJ) and cultured for 10
days with media changes every 3–4 days. Control cells
were cultured in completed DMEM media. Cells are sub-
sequently stained with AdipoRed (Cambrex) and visual-
ized under fluorescent microscopy.
Osteogenic differentiation
ERC were seeded at a concentration of 1 × 10[4] cells/ml
in an 8 well chamber slide (Lab-Tek) with 0.5 ml com-
pleted DMEM media per well. After the cells adhere over-
night, the medium is changed to the Osteogenic
Induction media (Cambrex). Cultures were cultured for
21 days with medium changes every 3–4 days. Control
cells were cultured in complete DMEM. Cells were stained
with Alizarin Red (ScholAr Chemistry, West Henrietta,
NY) and visualized.
Endothelial differentiation
ERC cells were seeded at a concentration of 1.9 × 10[4]
cells/ml in an 8 well chamber slide (Lab-Tek) with 0.5 ml
complete DMEM per well. After the cells were cultured
overnight the media was changed to the Endothelial
Induction media (Cambrex). Cells were cultured for 21
days with media changes every 3–4 days. Control cells
were cultured in complete DMEM. Cells are stained with
anti-CD34 and anti-CD62 (Ancell) followed by fluoures-
cently tagged secondary antibody.
Neurogenic differentiation
ERC cells were seeded at a concentration of 1.6 × 10 [4]
cells/ml in an 8 well chamber slide (Lab-Tek) with 0.5 ml
complete DMEM. After the cells adhered overnight, the
media was changed to the NPMM neural induction media
(Cambrex #CC-3209) and supplemented with 1% peni-
cillin/streptomycin, 0.2 mM glutamax (Invitrogen) and
hFGA-4 (Sigma F8424, 20 ng/ml). Cultures were cultured
in induction or control complete DMEM media for 21
days with media changes every 3–4 days. Cells were
stained with GFAP (Sigma) and Nestin (Chemicon), con-
jugated goat anti-mouse antibody (Bethyl Montgomery,
Texas).
Pulmonary epithelial differentiation
ERC were seeded at a concentration of 2 × 10 [4] cells/ml
on 8 well chamber slides (Lab-Tek) with 0.5 ml complete
DMEM per well. When the cells reach 100% confluency
the media was changed to induction medium (SAGM,
Cambrex). Cultures were cultured for 10 days with media
changes every 3–4 days. Control cells were cultured in
complete DMEM media alone. Cells were stained with
ProSP-C (Chemicon) plus conjugated Goat Anti-rabbit
(Invitrogen).
Hepatic/pancreatic differentiation
ERC were seeded at a concentration of 2 × 10[4] cells/ml
in an 8 well chamber slide (BD Biosciences #354630)
with 0.5 ml CM20 per well. After the cells adhere over-
night, the medium is changed to the induction medium
(Cambrex) supplemented with hepatocyte growth factor
(40 ng/ml), b-FGF (20 ng/ml), hFGF-4 (20 ng/ml), SCF
(40 ng/ml) (all from Sigma). Cultures were maintained
for 30 days with media changes every 3–4 days. Cells were
stained with antibodies to Albumin (R&D #MAB1455)
and insulin and developed plus secondary goat Anti-
mouse (Bethyl #A90-216F) and mouse anti-rat (Serotec),
respectively.
Cardiogenic and myogenic differentiation
8 well chamber slides were pre-coated with fibronectin
(Sigma #F2006) and ERC were seeded at a concentration
of 1.9 × 10[4] cells/ml. After overnight culture adherent
cells were treated with complete DMEM containing 10 µM
5-Azacytidine (Sigma) for 24 hours. Subsequently the
cells were cultured for 14 days in Skeletal Muscle Growth
Medium (Cambrex) supplemented with 100 ng/ml b-FGF
(Sigma). Cells were stained with Alpha-Actinin (Abcam)
for myocyte and Skeletal Myosin (Abcam, Cambridge
MA) for skeletal myocyte. For the cardiogenic differentia-
tion, cultures are allowed to develop for 40 days with
medium changes every 3–4 days and stained with Tro-
ponin I (Abcam #AB19615) plus conjugated Goat Anti-
mouse (Bethyl #A90-216F). In some experiments cells
were grown as hanging drop cultures as described [28] in
order to visualize beating. Briefly, 30–50 µl of cells were
placed on a lid of a petri-dish (Becton Dickinson Falcon
#35–3002) and 5–9 ml sterile PBS to bottom of dish to
maintain a humidified environment. Beating cells were
detected after 5 days.
Results
Isolation and cloning of cells
Given the hyperproliferative state of the endometrium
during preparation for implantation, and previous find-
ings of bone marrow derived cells in the endometrium
[13], we hypothesized that stem cell populations may be
present in menstrual blood. To assess this possibility, 5 ml
of menstrual blood was collected by urine cup-tubing
method in an antibiotic containing solution. Mononu-
clear cells were separated by standard Ficoll methodology
and grown in complete DMEM medium supplemented
with 20% FCS. After overnight culture cells revealed mar-
ginal adherence to the tissue culture flask (Figure 1a).
Cells were cultured for 2 weeks with media changing twice
a week. At the completion of 2 week culture, an outgrowth
of adherent cells with a fibroblast-like morphology was
observed (Figure 1b). In order to define a clonal popula-
tion of cells, we derived cell lines by single-cell plating in
96 well plates. We generated 2 cell lines, ERC-1 wasJournal of Translational Medicine 2007, 5:57 http://www.translational-medicine.com/content/5/1/57
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Morphology of Cultured ERC Figure 1
Morphology of Cultured ERC. A) Morphology of freshly isolated menstrual blood mononuclear cells. B) Fibroblast-like 
morphology of menstrual blood mononuclear cells after 2-week cell culture. C) Clonal population of menstrual cells after plat-
ing in 96 well plate 1 week after cloning. D) The same population 2 weeks after cloning.Journal of Translational Medicine 2007, 5:57 http://www.translational-medicine.com/content/5/1/57
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derived by single-cell plating in 96 well plates, which
revealed clonogenic potential (Figure 1c and 1d). The
experiment was replicated with cells derived from an addi-
tional donor, which gave rise to cell line ERC-2. The cells
grew at a doubling time of approximately one doubling
every 19.4 hours based on quantification of cell number
using microscope counting. These cells were named
"endometrial derived regenerating cells" ERC based on
their source and ability to differentiate into various tissues
as described onwards.
Characterization
Growth of ERC in culture appeared to be distinct from
control BioE purchased cells, as well as our internally
derived cord blood mesenchymal stem cells. Specifically,
it appeared that ERC proliferated at a substantially faster
rate as compared to the control mesenchymal cell popula-
tions. When stable cultures were compared after 20 dou-
blings ERC had a doubling rate of 0.81 days, whereas
control cells doubled in approximately 1.5–2 days (data
not shown). Given the ERC appeared to have a mesenchy-
mal-like morphology, but faster proliferative rate, we per-
formed a series of experiments to characterize expression
of mesenchymal and non-mesenchymal markers to fur-
ther characterize the cells. Flow cytometric analysis
revealed expression of CD9, CD44, CD29, CD41a, CD59,
CD73, CD90 and CD105, while lacking CD14, CD34,
CD38, CD45, CD133, STRO-1. This profile reflects a non-
hematopoietic stem cell phenotype. However, some of the
markers expressed are not unique to mesenchymal stem
cells and are found in other tissue resident stem cells,
therefore it appeared that ERC do possess some character-
istics that distinguish them from mesenchymal stem cells
obtained from bone marrow or cord blood (Table 1). Of
notable interest, mesenchymal stem cells, including those
reported in the endometrial wall itself are known to
express STRO-1 [29]. ERC were negative for expression of
this marker, but also negative for hematopoietic markers
such as CD34, CD45 and CD133. Most interestingly the
cells expressed hTERT and the embryonic stem cell marker
OCT-4.
Accordingly we sought to compare expression of proteins
related to stem cell functionality between commercially
available cord blood derived mesenchymal cells (BioE),
cord blood mesenchymal stem cells generated by us
(MYZb) and ERC. As seen in Table 2, expression of matrix
metalloproteases (MMP-3 and MMP-10), cytokine growth
factors (GM-CSF, PDGF-BB), and angiogenic factors
(ANG-2) was constitutively present in the culture media
of ERC cells in comparison to control cord blood mesen-
chymal stem cells which were lacking or minimally
expressed these proteins. Comparable secretion of ang-
iogenic factors such as VEGF, HGF, and EGF was observed
Table 1: Phenotypic Characterization of ERC
Marker Relevance Expression
CD14 Monocyte marker Negative
CD34 Hematopoietic stem cell marker Negative
CD38 Differentiating hematopoietic stem cell marker Negative
CD45 Pan-leukocyte marker Negative
CD133 Hematopoietic/angioblast marker Negative
STRO-1 MSC marker Negative
SSEA-4 Embryonic stem cell marker Negative
Nanog Embryonic stem cell marker Negative
CD9 MSC marker, associated with angiogenesis1 Positive
CD29 Adhesion molecule on mesenchymal and hepatic stem cells2 Positive
CD59 Complement inhibitor protein found on MSC3 and bone marrow side population CD34-stem cells4 Positive
CD73 Ecto-5'-nucleotidase, involved in migration of MSC Positive
CD41a Receptor for fibrinogen and vWF, found on MSC and platelets Positive
CD44 Hyaluronic acid receptor found on tissue stem cells and MSC Positive
CD90 Marker of T cells, hematopoietic and MSC Positive
CD105 Marker of tissue and MSC Positive
hTERT Telomerase reverse transcriptase Positive
Oct-4 Embryonic stem cell marker Positive
1 Kim YJ, Yu JM, Joo HJ, Kim HK, Cho HH, Bae YC, Jung JS. Role of CD9 in proliferation and proangiogenic action of human adipose-derived 
mesenchymal stem cells. Pflugers Arch. 2007 Aug 1.
2 Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, Miyoshi H, Nakano M, Zen Y, Nakanuma Y, Nakauchi H, Iwama A, Taniguchi H. 
Enhanced Self-Renewal Capability in Hepatic Stem/Progenitor Cells Drives Cancer Initiation. Gastroenterology. 2007 Jun 20;
3 Izadpanah R, Joswig T, Tsien F, Dufour J, Kirijan JC, Bunnell BA. Characterization of multipotent mesenchymal stem cells from the bone marrow of 
rhesus macaques. Stem Cells Dev. 2005 Aug;14(4):440–51.
4 Preffer FI, Dombkowski D, Sykes M, Scadden D, Yang YG. Lineage-negative side-population (SP) cells with restricted hematopoietic capacity 
circulate in normal human adult blood: immunophenotypic and functional characterization. Stem Cells. 2002;20(5):417–27.Journal of Translational Medicine 2007, 5:57 http://www.translational-medicine.com/content/5/1/57
Page 6 of 10
(page number not for citation purposes)
between all cells (data not shown). Cumulatively, our
characterization studies suggest that ERC share some
properties of mesenchymal stem cells based on pheno-
type, but functionally produce factors that are unique.
Differentiation
Given the phenotypic, morphological, proliferation and
secretory products of the ERC, we next questioned
whether these cells were capable of differentiating into
various lineages as described for other stem cell types. Dif-
ferentiation into mesodermal (myocyte, osteocyte,
endothelium, adipocyte, cardiomyocyte), ectodermal
(neuronal) and endodermal (hepatic, pancreatic, respira-
tory epithelium) lineages was demonstrated by culturing
of ERC using standard commercially available culture rea-
gents and methodologies. As seen in Figure 2, subsequent
to treatment with differentiation inducing protocols, ERC
appeared to express markers of various cell lineages as
detected by immunohistochemistry. ERC grown in con-
trol media in absence of differentiation stimuli did not
express markers of differentiation (data not shown). In
order to assess ability to form functional tissue, differenti-
ation along the cardiomyocyte lineage was performed
using the published 5-azacytidine hanging-drop method
[14]. Subsequent to a 5 day culture, spontaneously con-
tracting cells were observed. Overall, these data indicate
that ERC possess the potential to differentiate into cells of
all three germ lines.
Karyotype analysis
Utility of any stem cell population depends on ability of
expansion with freedom from carcinogenic potential. The
rapid doubling rate of the ERC (1 doubling every 19.4
hours), as well as lack of spontaneous differentiation in
absence of induction stimuli, suggests that large-scale
expansion is possible for therapeutic purposes. However,
in order to be useful, the cells must maintain karyotypic
normality. Karyotypic analysis was performed according
to routine methods, briefly, ERC were treated with colch-
icine and stained with DAPI for the chromosome analysis
[15]. Figure 3 shows 23 pairs of chromosomes from ERC
cells, after 38 and 68 cellular doublings. Twenty-one met-
aphases were imaged and sixteen cells were karyotyped
with G-banding analysis. Detailed analysis shows a nor-
mal karyotype of 46 chromosomes with no aneuploidy,
tetraploidy or other visible abnormalities. This suggests
that at least at the chromosomal level ERC are capable of
large scale expansion without mutagenesis.
Discussion
Given that stem cell populations are generally associated
with conditions of cellular hyperproliferation and tissue
remodeling, we have examined the possibility of stem
cells isolated from menstrual blood. While previously it
was suggested that mesenchymal stem cells are found in
endometrial tissue [13], numerous other tissues also have
been found to possess endogenous mesenchymal stem
cell populations which do not necessarily correlate with
angiogenesis. For example cells with mesenchymal stem
cell properties have been found in liver [16,17], lung [18],
skin [19], pancreatic [20] and kidney tissues [21]. It was
our hypothesis that the extreme angiogenesis occurring
during the build-up of the endometrium would allow for
specialized populations of stem cells to accumulate which
could be extracted by culture of menstrual blood. We
observed that the adherent fraction of menstrual blood
cells could be expanded up to 68 doublings without los-
ing karyotypic normality or developing tumorigenic
potential. The cells appeared to possess some markers of
mesenchymal stem cells such as CD9, CD29, CD41a,
CD44, CD59, CD73, CD90, and CD105 while lacking
hematopoietic stem cell markers such as CD14, CD31,
CD33, CD34, CD133, and the pan-leukocyte marker
CD45. Additional characteristics however make this a
unique population from endometrial mesenchymal stem
cells based on: 1) higher rate of proliferation compared to
control cord blood derived mesenchymal stem cells; 2)
lack of STRO-1 expression; 3) expression of the embryonic
stem cell marker Oct-4; and 4) high expression of matrix
metalloproteases. Given the ability of these cells to differ-
entiate into tissues representative of all three germ layer
components, we have named these cells "endometrial
regenerative cells" (ERC).
ERC appear to have high rate of proliferation in compari-
son to other control mesenchymal stem cells. The positive
expression of Oct-4, but negative expression of Nanog and
SSEA-4 on these cells may be similar in some ways to
amniotic fluid derived stem cells in that they express some
but not all embryonic stem cell markers as well as telom-
erase reverse transcriptase [9]. One drawback of our exper-
iments is that we did not perform functional assessment
of telomerase activity using TRAP assays. These experi-
ments are currently underway.
The possibility of ERC to be shed endometrial tissue-resi-
dent mesenchymal stem cells seems unlikely in light of
several findings. Specifically, tissue stem cells of the
endometrium have previously described to be bone mar-
Table 2: Proteomic Characterization of ERC Secreted Proteins
Factor BioE MYZb ERC-1 ERC-2
MMP3 05 0 106227 234638
MMP10 0 0 5250 8944
GM-CSF 0 452 15630 972
PDGF-BB 0 0 12 61
ANG-2 0 0 11 34
5 all concentrations expressed as (pg/million cells).Journal of Translational Medicine 2007, 5:57 http://www.translational-medicine.com/content/5/1/57
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Pluripotent Differentiation Figure 2
Pluripotent Differentiation. ERC were cultured under appropriate differentiation media as described in Materials and 
Methods and assessed for differentiation using the indicated staining methods. A) Adipocytic differentiation, yellow indicates 
lipid vacuoles stained by AdipoRed. B) Osteocytic differentiation, red indicates calcium stained by Alizarin Red. C) Myocytic dif-
ferentiation, green indicates alpha actinin stain. D) Skeletal muscle differentiation, green indicates skeletal myosin stain. E) 
Endothelial differentiation, green indicates CD34 stain. F) Endothelial differentiation, green indicates CD62 stain. G) Hepato-
cytic differentiation, morphology resembles hepatic body. H) Hepatocytic differentiation, green indicates albumin stain. I) Pan-
creatic differentiation, green indicates insulin stain. J) Neuronal differentiation, green indicates Nestin stain. K) Neuronal 
differentiation, green indicates GFAP stain. L) Respiratory epithelial differentiation, green indicates Prosurfactant protein C 
stain. M) Cardiogenic differentiation, green indicates Troponin I stain.Journal of Translational Medicine 2007, 5:57 http://www.translational-medicine.com/content/5/1/57
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Normality of Karyotype Figure 3
Normality of Karyotype. ERC were cultured for the indicated cell passage numbers and assessed for lack of karyotypic 
abnormalities. A. ERC at Passage 10 (38 doublings). B. ERC at Passage 18 (68 doublings). Both detailed analyses shows normal 
karyotypes of 46, XX.Journal of Translational Medicine 2007, 5:57 http://www.translational-medicine.com/content/5/1/57
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row derived and to express CD34 and CD45 [22], markers
which are not found on ERC. Tissue mesenchymal-like
stem cells from the endometrium express STRO-1 (13a), a
marker not found on ERC. Additionally, the proliferative
rate of ERC (1 doubling every 19.4 hours) appears to be
faster than that described for cells derived from putative
uterine derived stem cells [23]. Finally, it is interesting
that culture of ERC with specific "differentiation media"
was able to generate cells of all three germ lines, some-
thing which has not been reported for endometrial tissue
stem cells. One possible explanation for the pluripotency
of ERC may be that these cells have some relationship to
the "circulating oocyte progenitors" described by Tilly's
group. Specifically, it was reported that bone marrow
derived cells have the potential to transdifferentiate into
oocyte precursors and that the presence of these cells in
peripheral blood and bone marrow fluctuated with men-
strual phase [24]. We are in the process of assessing ERC
for expression marker's reported to be found on circulat-
ing oocyte precursors such as Vasa, Dazl and Stella.
Another possibility is that ERC are involved in the angio-
genesis phase of the menstrual cycle and contribute to the
high level of tissue remodeling. In agreement with this
hypothesis is the high level of matrix metalloprotease and
growth factor production in comparison to control mes-
enchymal stem cell lines.
Regardless of biological significance, ERC appear to pos-
sess numerous advantages compared to other stem cell
sources that make them attractive of future investigation.
Firstly, the ease of collection of ERC allows for the crea-
tion of patient-specific banking. Given that the cells are
expandable, as well as possessing ability to differentiate
into various tissues, the cells can not only be banked until
future use, but can also be expanded and pre-differenti-
ated into various tissues so that patient-specific tissues are
"on standby' and ready for use when needed. Other stem
cell sources such as bone marrow and adipose tissue do
not allow for such wide-spread expansion and ease of col-
lection. Secondly, the finding that the cells can be
expanded for 68 doublings without evidence of karyo-
typic or functional abnormalities implies that from one
starting cell enough cells theoretically can be produced to
treat every human being in the world. This relatively
unlimited potential allows for generation of unique cell
lines that can be transfected with different genes to induce
specific effects. For example, cell lines can be engineered
with angiogenic agents [25], neurotrophic factors [26], or
to express insulin [27]. Lastly, ERC appear to have several-
fold higher expression of matrix metalloproteases as com-
pared to stem cells of other lineages. Physiologically, it is
known that major remodeling of tissue is associated with
the process of menstruation. Given the potential role of
these cells in remodeling the endometrium, it may be rea-
sonable to suggest that these cells are useful for treatment
of fibrotic conditions such as cirrhosis in which regenera-
tive cells with tissue degradation activities are desired.
These possibilities are currently under investigation by
our laboratory.
In conclusion, we have discovered a novel stem cell source
from the menstrual blood that is easily accessible, highly
expandable in vitro, and possesses pluripotency. This cell
population may become a practical solution of choice for
autologous stem cell therapy.
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